RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Brand Name :
OptiMARK
Synonyms :
gadoversetamide
Class :
Nonionic/ High Osmolality, magnetic resonance imaging contrast media
Dosage Forms & Strengths
Injectable solution
330.9 mg/mL
0.2 mL/kg IV and infuse at rate of 1-2 mL/sec
Note: Indicated for use with MRI (abnormal, spine, and associated tissues) and visualize the abnormal vascularity lesions in liver
Adverse drug reactions
Frequency Defined
1-10%
Diarrhea (1.9%)
Abdominal pain (1.8%)
Paresthesia (2.2%)
Headache (9.4%)
Back pain (1%)
Dyspepsia (1%)
Vasodilation (6.4%)
Rhinitis (2%)
Injection site reaction (2%)
Dizziness (3.7%)
Nausea (3.2%)
<1%
Amblyopia
Dry skin
Dystonia
Flatulence
Anorexia
Cough
Seizures
Diplopia
Pregnancy warnings:
Pregnancy Category: C
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were no enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: gadoversetamide
Why do we use gadoversetamide?
gadoversetamide is an magnetic resonance imaging contrast media used for CNS/Liver MRI (Magnetic Resonance Imaging)